SSTR2 and neuroendocrine neoplasm: In a study, SSTR2 radiolabeled with Yitrium-90-DOTATOC (90Y-DOTATOC) and Lutetium-177- DOTATATE (177Lu-DOTATATE) was used on neuroendocrine tumors (NETs) as a new radiopharmaceutical therapy.